Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Trial details
- Registry ID
- NCT07474792
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792 | ORKA | Phase 2 | Active not recruiting | 2027-10Estimated |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaNCT07783542 | ORKA | Phase 2 | Recruiting | 2028-10Estimated |
| An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque PsoriasisNCT07933783 | ORKA | Phase 2 | Enrolling by invitation | 2029-07-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |